// App-Quantinova.ai

TPS8056 : A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).

Researchers

Presenter

  • Sosana Delimpasi

Principal Investigators

  • Ludek Pour

  • Holger W Auner

  • Meletios A. Dimopoulos

  • Alon Rappaport

  • Lisa Fortin

  • Jatin J. Shah

  • Sharon Shacham

  • Michael G. Kauffman

  • Nizar J. Bahlis

Medical Centers

  • General Hospital of Athens, Athens, Greece

  • University Hospital Brno, Brno, Czech Republic

  • National and Kapodistrian University of Athens, Athens, Greece

  • Karyopharm Therapeutics, Newton, MA

  • Tom Baker Cancer Center, Calgary, AB, Canada

Locations

  • Czech Republic

  • Canada

  • Greece

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bortezomib

  • Selinexor

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT03110562

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved